Trial Condition(s):

Multiple Sclerosis, Relapsing-Remitting

QOLBET Quality Of Life in patients with early relapsing-remitting multiple sclerosis treated with BETaferon® in Korea

Bayer Identifier:

15110

ClinicalTrials.gov Identifier:

NCT01071694

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Inclusion Criteria
- Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs
  - Patients who signed informed consent form
Exclusion Criteria
- Age lower than 18

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, South Korea

Status
Not yet recruiting
 

Trial Design